Featured Archives - OMNY Health

What a week at ISPOR 2026!

The OMNY Health team had a highly productive and impactful showing at this year’s annual conference. We anchored our presence with one podium presentation and six poster presentations—including a standout client-led poster utilizing OMNY Health data.

Our featured research spanned a diverse array of therapeutic areas, economic evaluations, and advanced methodological frameworks, demonstrating our robust capabilities in health economics and outcomes research (HEOR). From mental health and metabolic outcomes to respiratory and immunology research, these studies highlight the critical role that high-quality real-world data (RWD) plays in modern evidence generation.

Beyond our own presentations, our team spent the week engaging with the definitive themes shaping the future of HEOR: the evolution of AI adoption and advanced evidence generation in oncology.

A major takeaway from the sessions on AI and Large Language Models (LLMs) is the critical shift from manual abstraction to automated, scalable data enrichment.

The Challenge: The industry faces an unprecedented demand for RWD, but a massive volume of clinical narrative remains locked in unstructured electronic health records (EHRs) and physician notes. Traditional manual abstraction is costly, slow, and unsustainable.

The Methodological Solution: Discussions highlighted advanced AI optimization frameworks—splitting AI into Machine Learning (ML) for predictive risk profiling and Natural Language Processing (NLP) for clinical text recognition. Leading methodologies are deploying multi-layered approaches (combining web scraping, PDF processing, and rule-based parsing with prompt-specific LLMs) alongside quality frameworks like the Kahn Framework to eliminate false negatives and capture missing variables (such as nuanced Social Determinants of Health).

The OMNY Advantage: At OMNY Health, this is exactly where our AI services add distinct value. By converting unstructured text into structured, normalized data spaces , we bypass traditional site-visitation. We augment existing HEOR methods to deliver high-fidelity, generalizable datasets ready for advanced applications like digital twins and regulatory-grade evidence generation.

Oncology continues to be a frontier where conventional evidence paradigms fall short, especially as discussed in the cancer plenary on the financial toxicity of care and the rare cancer forums.

The Challenge: Generating credible real-world evidence (RWE) in oncology—particularly rare cancers—is routinely restricted by small sample sizes, single-arm designs, and highly fragmented data across the care continuum. Furthermore, regulatory bodies and Health Technology Assessment bodies (HTAbs) demand strict adherence to data quality frameworks.

The Methodological Solution: To accelerate market access and build stakeholder trust, the industry is moving toward advanced methods like target trial emulation, external control arms, and robust EHR-derived data quality frameworks to validate longitudinal patient journeys.

The OMNY Advantage: Our specialized oncology data offering directly answers this call. OMNY’s large, US-based oncology EHR-derived database is built with rigorous regulatory data quality frameworks in mind. By integrating medicines, molecular testing, and medical services across the care continuum, we provide life sciences companies and researchers with the deep, longitudinally complete data required to evaluate complex variables, track treatment adherence, and demonstrate true patient-centered value.

A huge thank you to everyone who stopped by our sessions, visited our posters, or took the time to connect with our team! We loved catching up with familiar faces and sparking new collaborations.

The conversations we had reinforce how vital high-quality RWD and intelligent AI extraction are to shaping the future of healthcare. We’re looking forward to continuing these discussions, supporting regulatory buy-in, and driving the industry forward together.

Missed us at the event but want to learn more about our advanced oncology data capabilities or AI-driven RWD solutions? Let’s connect!

ATLANTA, GA — OMNY Health today announced a major expansion of its healthcare data ecosystem, now representing more than 175 million de-identified longitudinal patient lives. This milestone — containing nearly half of the U.S. population — solidifies OMNY Health as the nation’s largest, most representative commercial source of first-party, provider-led clinical Real-World Data (RWD).

This growth is powered by targeted expansions across Integrated Delivery Networks (IDNs), community hospitals, Academic Medical Centers (AMCs), and large multi-state specialty groups. By capturing data directly from the point of care, OMNY provides the healthcare and life sciences industry with unparalleled access to diverse patient journeys at a national scale.

Bridging the “Why” Gap in Cancer Research

In tandem with this network expansion, OMNY has launched OMNY Foundation: Oncology, a specialty product suite designed to bridge critical data gaps in cancer research. While traditional datasets often lack pre-diagnosis and post-treatment context, OMNY’s solution provides deep insights from the full patient journey for over 10 million oncology patient journeys (2017–Present).

Consistent with OMNY’s other therapeutic-specific solutions, the oncology product uniquely integrates downloadable structured EHR data and holistic administrative claims data with de-identified clinical notes and diagnostic reports (e.g., radiology, pathology). This allows researchers to peer into the “narrative” of care — capturing physician rationale, therapy selection strategies, and the nuances of treatment planning that structured fields alone miss.

Regulatory-Grade Depth for External Control Arms

The OMNY Foundation: Oncology suite was engineered to meet the FDA’s stringent “Fit-for-Purpose” criteria, making it a viable asset for regulatory submissions and External Control Arms (ECAs). Key features include:

“Whole-Patient” Visibility: Seamlessly links oncology records with cardiovascular, metabolic, and primary care data to monitor pre-diagnosis history, comorbidities, and long-term survivorship.
Precision Variables: Direct access to granular data including tumor staging, treatment plans, mutation data, and molecular biomarkers (e.g., EGFR, ALK, PD-L1).
Auditability & Provenance: A transparent digital “paper trail” connects every data point to its source clinical event, ensuring the rigorous transparency required for high-stakes regulatory evidence.
Integrated Outcomes: Pre-linked 3rd-party administrative claims and mortality information provide a comprehensive view of care delivery, in addition to treatment response variables and long-term survival.

“Our goal is to transition the industry from ‘big data’ to ‘deep data,'” said Mitesh Rao, MD, CEO of OMNY Health. “By capturing the modern era of oncology screening and care across our more than 175 million patients, we provide the scale of a national aggregator with the clinical nuance usually possible in a specialty registry. We are delivering the high-resolution evidence required to answer the most complex questions in medicine today.”

About OMNY Health

OMNY Health is a premier healthcare data ecosystem that facilitates the secure exchange of clinical real-world data (RWD). By bridging the gap between healthcare providers and the life sciences community, OMNY accelerates medical breakthroughs and improves patient outcomes. In addition to its new Oncology product suite, OMNY maintains specialized RWD products in Dermatology, Ophthalmology, Gastroenterology, Respiratory, Cardiology, and Neurology therapeutic areas.

For more information, visit: www.omnyhealth.com

Media Contact: media@omnyhealth.com